drugset / Trial / NCT00548691
Safety and Tolerability of FCM vs Standard of Care in Treating Iron Deficiency Anemia in Chronic Kidney Disease Patients
RandomizedParallel-groupOpen-labelTreatment
Summary
The Objective of this study is to study the safety of FCM in patients with anemia caused by chronic kidney failure
Timeline
- Start
- 2007-10
- Primary completion
- 2009-01
- Completion
- 2009-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ferric carboxymaltose | Other / unclassified | 15 mg/kg | Intravenous |
| Subject | Ferric carboxymaltose | Other / unclassified | 200 mg | Intravenous |